News

Overcoming why a new treatment is resisted by lung cancer


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Overcoming why a new treatment is resisted by lung cancer

 

Date: 30/07/2015

A promising agent for the treatment of cancer has so far had little effect on the most common lung tumours, but new research from The University of Manchester has suggested how this resistance might be overcome.

In two papers released in the journal PNAS, the research team examined factors which mean that the most common type of lung cancer – itself the most common cause of cancer deaths – is resistant to a cytokine called TRAIL that causes cell death in many other types of tumour.

The researchers found that in non-small cell lung cancer, which accounts for around 85 percent of cases, a small RNA molecule called miR-148a is suppressed in TRAIL resistant cells, but that when used together, miR-148a sensitises tumour cells to TRAIL and results in the tumour shrinking.

For more click here

Source: University of Manchester

© Catalyst Innovation Portal 2019